Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Incretin manipulation in diabetes management.

Literature DB >> 26131320

Incretin manipulation in diabetes management.

Joseph M Pappachan¹, A V Raveendran¹, Rajagopalan Sriraman¹.

Abstract

Incretin-based therapies have revolutionized the medical management of type 2 diabetes mellitus (T2DM) in the 21(st) century. Glucagon-like peptide-1 (GLP-1) suppresses appetite and gastric motility, and has trophic effects on pancreas, cardio-protective and renal effects. GLP-1 analogues and dipeptidyl peptidase-4 inhibitors form the incretin-based therapies. Significant reduction of hemoglobin A1c when used as monotherapy and in combination regimens, favorable effects on body weight, and low risk of hypoglycemia are their unique therapeutic benefits. Their safety and tolerability are comparable to other anti-diabetic medications. Concern about elevated risk of pancreatitis has been discarded by two recent meta-analyses. This article discusses the therapeutic manipulation of incretin system for the management of T2DM.

Entities: Disease Gene

Keywords: Dipeptidyl peptidase-4 inhibitors; Glucagon-like peptide-1 analogues; Incretin hormones; Incretin-based therapies; Pancreatitis

Year: 2015 PMID： 26131320 PMCID： PMC4478574 DOI： 10.4239/wjd.v6.i6.774

Source DB: PubMed Journal: World J Diabetes ISSN： 1948-9358

40 in total

1. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors: S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews
Journal: Diabetologia Date: 2012-04-20 Impact factor: 10.122

2. Standards of medical care in diabetes--2014.

Authors:
Journal: Diabetes Care Date: 2014-01 Impact factor: 19.112

Review 3. The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials.

Authors: Shekoufeh Nikfar; Mohammad Abdollahi; Pooneh Salari
Journal: J Pharm Pharm Sci Date: 2012 Impact factor: 2.327

Review 4. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.

Authors: Josephine M Egan; Angela Bulotta; Hongxiang Hui; Riccardo Perfetti
Journal: Diabetes Metab Res Rev Date: 2003 Mar-Apr Impact factor: 4.876

5. Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension.

Authors: S-M Jin; S W Park; K-H Yoon; K W Min; K-H Song; K S Park; J-Y Park; I B Park; C H Chung; S H Baik; S H Choi; H W Lee; I-K Lee; D-M Kim; M-K Lee
Journal: Diabetes Obes Metab Date: 2015-01-14 Impact factor: 6.577

Review 6. Clinical review of sitagliptin: a DPP-4 inhibitor.

Authors: Kamlesh Garg; C D Tripathi; Surinder Kumar
Journal: J Assoc Physicians India Date: 2013-09

Review 7. Glycaemic control in type 2 diabetes: targets and new therapies.

Authors: Abd A Tahrani; Milan K Piya; Amy Kennedy; Anthony H Barnett
Journal: Pharmacol Ther Date: 2009-11-18 Impact factor: 12.310

8. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

Authors: Mark S Fineman; Thomas A Bicsak; Larry Z Shen; Kristin Taylor; Eling Gaines; Amanda Varns; Dennis Kim; Alain D Baron
Journal: Diabetes Care Date: 2003-08 Impact factor: 19.112

Incretin manipulation in diabetes management.

1. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

2. Standards of medical care in diabetes--2014.

Review 3. The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials.

Review 4. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.

5. Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension.

Review 6. Clinical review of sitagliptin: a DPP-4 inhibitor.

Review 7. Glycaemic control in type 2 diabetes: targets and new therapies.

8. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

9. Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis.

10. Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes.

Review 1. Teneligliptin: a review in type 2 diabetes.

Review 2. Diabetes-related dysfunction of the small intestine and the colon: focus on motility.

Review 3. Medical Management of Diabesity: Do We Have Realistic Targets?

Review 4. Non-alcoholic Fatty Liver Disease: A Clinical Update.